PrimeRFP SCOUT · Federal Contract Recompete Brief

36C26223N0443VISN 22 WIDE infectious molecular pathology — Roche Diagnostics Corp

Roche Diagnostics Corp holds $245.9M across 1,391 federal awards, concentrated at Department of Veterans Affairs (VA). This PIID sits alongside 5 related awards under parent 36C26218A0021. The prior award was single-bid — competitive dynamics may favor a challenge. Set-aside status: NONE. PoP ended Oct 11, 2024 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

262-Network Contract Office 22 (36C262)

Awarding office

Roche Diagnostics Corp

Recipient

Oct 11, 2024

PoP end

$1.7M

Obligated

$1.8M

Potential

334516

NAICS

6640

PSC

NONE

Set-aside

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Roche Diagnostics Corp — $90

Contract facts

NONE

Contract number36C26223N0443

Also listed as36C262-23-N-0443

Also listed as36C26218A0021-36C26223N0443

Agency262-Network Contract Office 22 (36C262)

Awarding office262-Network Contract Office 22 (36C262)

Awarding agencyDepartment of Veterans Affairs (VA)

Funding agencyDepartment of Veterans Affairs (VA)

IncumbentRoche Diagnostics Corp

CAGE51169

UEIJDMDFEZBYH36

NAICS334516

No full NAICS 334516 intel page yet. Browse NAICS intelligence

PSC6640

Parent IDIQ / IDV36C26218A0021

Place of performanceINDIANAPOLIS IN

Pricing typeFirm Fixed Price

Extent competedCompeted Under SAP

PoP startApr 14, 2023

PoP end (current)Oct 11, 2024

Obligated$1.7M

Current value$1.8M

Potential value$1.8M

VISN 22 WIDE INFECTIOUS MOLECULAR PATHOLOGY COST-PER-TEST BPA is a federal NONE award for 262-Network Contract Office 22 (36C262) held by Roche Diagnostics Corp. Estimated value $1.8M ($1.7M obligated). Current period of performance ends Oct 11, 2024. Last award drew 1 bidder. Place of performance: INDIANAPOLIS IN.

VISN 22 WIDE INFECTIOUS MOLECULAR PATHOLOGY COST-PER-TEST BPA

Recompete timing

Public

● Past PoP end (680 days ago)

Current PoP ended Oct 11, 2024 (680 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Incumbent footprint

Public record

Roche Diagnostics Corp — $245.9M obligated across 1,391 awards (firm-wide, all agencies) · lead buyer Department of Veterans Affairs (VA).

% of firm-wide obligated ($245.9M) · all agencies

Department of Veterans Affairs (VA)$154.1M · 63%Department of Defense (DOD)$77.5M · 32%Department of Health and Human Services (HHS)$10.4M · 4%Department of Justice (DOJ)$3.0M · 1%

Open full company profile →

Related awards

Same parent · incumbent

36C26225N0151

CHEMISTRY IMMUNOASSAY SYSTEM CPT

$5.9M

Aug 31, 2026

36C25025N1021

FSS-BPA ROCHE COBAS 4800 REAGENTS, CONSUMABLES, CONTROLS.

$600K

Aug 31, 2026

FA480321F0055

ROCHE COVID TEST KITS

$159K

Aug 31, 2026

36C25025N1000

COBA REAGENTS/CONSUMABLES

$135K

Aug 31, 2026

36C25726P0473

BENCHMARK ULTRA PLUS

$132K

Aug 31, 2026

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 36C26223N0443?

36C26223N0443 (VISN 22 WIDE infectious molecular pathology) is a 262-Network Contract Office 22 (36C262) award with a potential value of $1.8M, currently held by Roche Diagnostics Corp. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C262-23-N-0443?

36C262-23-N-0443 is the dashed form of PIID 36C26223N0443 (VISN 22 WIDE infectious molecular pathology), held by Roche Diagnostics Corp. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C26223N0443?

262-Network Contract Office 22 (36C262) awarded 36C26223N0443 to Roche Diagnostics Corp (potential $1.8M).

Who is the incumbent on 36C26223N0443?

Roche Diagnostics Corp is the incumbent with $245.9M across 1391 related awards in SCOUT’s public footprint. The current period of performance ends Oct 11, 2024.

When does Roche Diagnostics Corp’s 36C26223N0443 come up for recompete?

SCOUT tracks a period-of-performance end of Oct 11, 2024. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 19, 2026 · refreshed monthlyLatest procurement action Feb 19, 2025